C ardiovascular disease causes one of every three deaths in the United States and costs this country about $450 billion annu ally. 1 Each year, despite recent improvements in prevention and treatment, heart disease kills near ly 600,000 Americans, and stroke kills nearly 130,000. People with a history of atherosclerotic cardio vascular disease (e.g., myocardial infarction, stroke, or peripheral arterial disease) are at significant ly elevated risk for a new or re current cardiovascular event and associated illness and death. It is estimated that more than 16 mil lion U.S. adults are living with coronary heart disease, including prior myocardial infarction and angina, another 7 million have had a stroke, and approximately 8 million currently have periph eral arterial disease. 2 Effective interventions for sec ondary prevention in these pa tients include lifestyle modifica tions such as smoking cessation, weight control, increased physical activity, and dietary modifications, as well as pharmacotherapy to control blood pressure and cho lesterol levels. Another important evidencebased intervention is the use of aspirin and other anti platelet agents (see the table in the  Supplementary Appendix, available with the full text of this article at NEJM.org). With few exceptions, patients with coronary heart dis ease, peripheral arterial disease, or a history of ischemic stroke are candidates for aspirin use.
The role of aspirin in the sec ondary prevention of myocardial infarction, stroke, and death from vascular causes is well established. Results from a metaanalysis of randomized trials of the Anti thrombotic Trialists' Collaboration have shown that aspirin can reduce the risk of recurrent major coro nary events and stroke by 20% and 19%, respectively. 3 In addition, a more recent Australian study shows that aspirin use for second ary prevention not only provides a health outcomes benefit, but may also result in cost savings: the number needed to treat to prevent any type of event (nonfatal myo cardial infarction, stroke, or death from any cause) was 48, and on average, the use of aspirin result ed in savings of $69 per person. 4 In light of this evidence, re cent data from the National Am bulatory Medical Care Survey and National Hospital Ambula tory Medical Care Survey of the Centers for Disease Control and Prevention on the recommended use of aspirin and other anti platelet medications in adults for the secondary prevention of car diovascular events are sobering. In 2007 to 2008, antiplatelet med ications were prescribed at only 46.9% of visits for patients with ischemic vascular disease (a rate that was virtually unchanged from the 2005-2006 period). In addi tion, general medicine or primary care physicians prescribed anti platelet medications for this pop ulation only 34.8% of the time (a decrease from 37.9% in [2005] [2006] . 5 The results of these sur veys and the strong evidence of the benefit of aspirin in terms of cardiovascular outcomes under score the substantial opportunity before clinicians and patients. Though some patients may not be receiving antiplatelet medica tions because of valid contraindi cations, the vast majority of these patients would be candidates.
Increasing aspirin use should be straightforward. Aspirin is an inexpensive, overthecounter drug that need be taken only once a day. In addition, clinical manage ment is relatively uncomplicated. Though current guidelines refer ence a range of doses, the gener ally accepted dose is 81 mg and does not require adjustment. There are no screening tests need ed or followup laboratory tests to guide aspirin therapy. From the patient's perspective, aspirin use does not require substantial be havior change or modification. Common barriers to aspirin use, such as lack of clarity regarding the benefit and mild but bother some bruising, can be addressed through informed and shared de cision making.
From the provider's perspec tive, the shifting guidance in the past regarding dosage and target population has contributed to less thanoptimal prescribing patterns. Uptake of current guidelines can be improved with focused com munications to all members of the medical team and by embed ding aspirin reminders within electronic health record systems. In addition, there are increasing numbers of incentives for clini cians and their organizations to focus on aspirin use for second ary prevention. The Physician Quality Reporting System includes measures of appropriate aspirin administration for secondary pre vention and will, in 2013, allow eligible professionals to earn a 0.5% incentive payment (based on all the services they provide that are covered by Medicare Part B) by satisfactorily reporting on a set of quality measures that can include aspirin use. Fortunately, there are also a number of broad public and pri vatesector initiatives under way to increase awareness and appro priate use of aspirin in secondary prevention. First, Million Hearts is a national initiative that aims to focus, coordinate, and enhance activities for cardiovascular dis ease prevention across the public and private sectors in an effort to prevent 1 million heart attacks and strokes by 2017. Million Hearts is scaling up proven clini cal and community strategies for preventing heart disease and stroke throughout the country by encouraging a targeted focus on aspirin for people at risk, blood pressure control, cholesterol man agement, and smoking cessation. The program will be providing materials for health care provid ers and the public that assist in translating the evidence into prac tice and help in achieving excel lence in a measure that pro foundly affects health.
Second, the appropriate admin istration of aspirin is an integral component of national efforts by many private and nonprofit organ izations to improve the quality of cardiovascular care. For example, the prescription of aspirin at dis charge for patients hospitalized for coronary heart disease or is chemic stroke has been a focus of the Get with the Guidelines Program of the American Heart Association and the Paul Coverdell National Acute Stroke Program of the Centers for Dis ease Control and Prevention. Counseling about regular use of aspirin is also one of the key ways to improve the quality of care and disease prevention in the outpatient setting according to the Guideline Advantage pro gram, a joint effort by the Ameri can Heart Association, the Amer ican Cancer Society, and the American Diabetes Association. The PINNACLE (Practice Innova tion and Clinical Excellence) pro gram of the American College of Cardiology allows participating clinicians to track their perfor mance in prescribing aspirin (among many other quality mea sures related to cardiovascular health) and provides benchmarks for comparison with other clini cians across millions of patient encounters.
There is an important and ur gent opportunity to engage all health care providers, particularly primary care providers, in a sin gular, simple intervention with the potential to prevent heart at tacks and strokes and save lives. Provision of aspirin to patients with coronary artery disease, ath erosclerotic peripheral artery dis ease, or a history of cerebrovas cular disease (transient ischemic attack or stroke) should be the norm; everyone without a contra indication should receive it. Clini cians need to be reminded of evi dencebased guidelines through continuing education and profes sional activities. In addition, sys tembased interventions such as clinical decision support and re inforcement by each member of the care team can ensure that all those who can benefit from aspi rin therapy receive it. Ultimately, many heart attacks and strokes can be prevented by simplifying the message to both clinicians and their patients with a history of coronary artery disease, periph eral vascular disease, or stroke and no allergy or recent history of bleeding: it's good medicine to take a daily lowdose aspirin.
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